PRTA - Prothena Corporation

-

$undefined

N/A

(N/A)

Prothena Corporation NasdaqGS:PRTA Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline includes birtamimab, an investigational humanized antibody, which in phase 3 clinical trial to treat patients with AL amyloidosis; and Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.

Location: 77 Sir John Rogerson’s Quay, Dublin, D02 VK60, Ireland | Website: https://www.prothena.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-21.25M

Cash

417.9M

Avg Qtr Burn

-32.59M

Short % of Float

19.49%

Insider Ownership

19.01%

Institutional Own.

88.72%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Birtamimab Details
Rare diseases, Amyloid light chain amyloidosis

Susp. Mover™

Phase 3

Data readout

BMS-986446 (PRX005) Details
Alzheimer's disease

Phase 2

Data readout

Coramitug (PRX004) Details
Rare diseases, Transthyretin amyloidosis

Susp. Mover™

Phase 2

Data readout

Prasinezumab Details
Neurodegenerative disease, Parkinson's disease

Phase 2

Update

PRX019 Details
Neurodegenerative disease

Phase 1

Data readout

PRX012 Details
Alzheimer's disease

Phase 1

Data readout

PRX123 Details
Alzheimer's disease

Phase 1

Initiation